SeaStar Medical (ICU) Q1 2026 earnings review
Pediatric Revenue Accelerates, But Adult Trial Pace Lags
SeaStar Medical delivered an accelerating 69% YoY revenue increase to $0.5 million in Q1, driven by the expansion of its QUELIMMUNE pediatric customer base. However, the company's primary valuation driver—the NEUTRALIZE-AKI adult pivotal trial—is flashing warning signs. Enrollment decelerated dramatically to just 17 patients this quarter (reaching 198 of 339). Mathematically, SeaStar must enroll roughly 47 patients per quarter to hit its year-end target, a steep ramp from current levels. With $9.3 million in cash and a $2.6 million quarterly operating burn, the financial runway remains stable into early 2027, but any clinical delays could force a dilutive capital raise.
🐂 Bull Case
The 69% jump in Q1 revenue confirms that hospitals are successfully navigating the lengthy IRB and registry requirements to adopt QUELIMMUNE for pediatric patients.
The SAVE Registry successfully met its 50-patient enrollment mandate. The preliminary data showing a 76% 60-day survival rate provides powerful real-world evidence to drive further adoption.
🐻 Bear Case
The NEUTRALIZE-AKI trial only added 17 patients in Q1, a sharp drop from the 35 patients added in the prior quarter. Achieving the 339-patient target by year-end looks increasingly improbable without a massive enrollment surge.
Management stated they added 7 top-rated children's hospitals in Q1 to reach a total of 17. Given that they reported 16 total customers at the end of 2025, this implies 6 previously reported customers are no longer part of the active base.
⚖️ Verdict: ⚪
Neutral. Commercial execution in the pediatric segment is strong and operating cash burn is highly disciplined. However, the sluggish pace of the adult AKI trial—the company's true blue-sky opportunity—presents a severe timeline risk.
Key Themes
QUELIMMUNE Pediatric Adoption
Commercial execution is accelerating. SeaStar expanded its reach by onboarding 7 new top-rated children's hospitals. This penetration into high-tier institutions provides essential clinical validation for the Selective Cytopheretic Device (SCD) platform, supporting the narrative that key opinion leaders are embracing the technology despite complex onboarding logistics.
NEUTRALIZE-AKI Enrollment Deficit
A critical discrepancy exists between the company's timeline guidance and its actual data. Management reiterated plans to complete the 339-patient NEUTRALIZE-AKI trial 'around the end of 2026.' Yet, Q1 saw only 17 new enrollments (bringing the total from 181 to 198). This represents a decelerating pace compared to Q4 2025. To hit the target, SeaStar must average 47 enrollments per quarter for the rest of the year—a nearly 3x acceleration that contradicts current momentum.
SAVE Registry Real-World Validation
The mandatory SAVE Registry hit its 50-patient enrollment target. More importantly, peer-reviewed publication in Pediatric Nephrology confirms no device-related safety events, a 76% survival rate at 60 days, and a 71% survival rate at 90 days. This validates a nearly 50% reduction in mortality compared to historical data, arming the sales team with irrefutable real-world evidence.
Regulatory Streamlining via Modular PMA
To mitigate potential delays, SeaStar has initiated the submission of a modular post-marketing application (PMA) for the adult AKI indication. Supported by the FDA's Breakthrough Device Designation, this rolling submission process allows the agency to review non-clinical data while the pivotal trial concludes, potentially shortening the gap between trial completion and commercial launch.
Customer Retention Discrepancy
The Q1 press release states the company 'added 7 new customers... bringing the total customer base to 17.' However, the company reported having 16 active customers at the end of FY25. This math implies that 6 previously counted hospitals churned or were reclassified. Management must clarify whether this represents actual customer attrition or a shift in how 'active' accounts are defined.
Tight Capital Position in a Tough Macro Environment
The company ended Q1 with $9.3 million in cash, down from $12.0 million at the end of 2025. While the $2.6 million quarterly operating burn is highly disciplined, the macro environment for micro-cap biotech capital raises remains punitive. If the NEUTRALIZE-AKI trial extends into 2027—which current enrollment rates suggest—the company will likely face a dilutive financing event before crossing the finish line.
Other KPIs
Stable. Down slightly from $2.4 million in 25Q1. The decrease was primarily driven by lower clinical trial costs, partially offset by increased personnel and external services costs. This highlights rigorous cost control despite advancing a pivotal trial.
Stable. Flat YoY compared to $1.7 million in 25Q1. An increase in legal and accounting expenses was successfully offset by declines in personnel and SEC-related costs.
Guidance
Accelerating. Implies roughly 62% YoY growth from FY25's $1.23 million. With $0.5 million already booked in Q1, the company is exactly on pace to hit this target.
Stable. The company targets adding 15 new top-ranked centers throughout FY26. Having secured 7 in Q1, they are pacing well ahead of this operational metric.
Decelerating. Management maintained guidance to complete enrollment around year-end. However, based on the drop to 17 enrollments in Q1, achieving this will require a massive operational turnaround at clinical sites.
Key Questions
Enrollment Acceleration Strategy
With only 17 patients enrolled in Q1 for the NEUTRALIZE-AKI trial, how exactly does management plan to nearly triple this quarterly run rate to meet the end-of-2026 completion target?
Customer Count Discrepancy
You ended 2025 with 16 pediatric hospitals and added 7 in Q1, yet the total reported is 17. Can you explain the attrition or reclassification of the missing 6 accounts?
PMA Modular Timeline
What specific modules of the PMA are currently being submitted, and how much FDA review time do you estimate this rolling process will shave off the backend?